A Strategic Approach to the Successful Development
of New Therapies End-to-End.
to meet stakeholder expectations and ensure commercial success?
A panel discussion with seasoned industry experts in Investor Relations, Medical Affairs, Market Access, and Media & Public Relations
Commercial success is the ultimate goal for any company developing a new therapy. Patients must need therapy, regulators must approve it, physicians must prescribe it, and payers must pay for it. The clearer and earlier this goal guides the development, and a compelling value story is told, the higher the level of trust from stakeholders along the long road from discovery to launch. However, clarity on the path to commercial success may be limited in early development stages, and resources are certainly limited. Thus, a strategic and integrated approach end-to-end is vital.
May 9, 2023 8:00am-9:30am EDT in Boston MA
Kasia is an advisor and founder in MedTech and digital health startup companies, a mentor in two incubators (mHUB in Chicago, and StartUpNV in Las Vegas), and the founder of Abante Scientific, which offers innovation management consulting, and the SciencePreneur Academy that teaches a strategic DIVE (Discovery-Innovation-Value-Execution) framework for life science companies to create leading brands and help patients to access innovative treatments.
Kasia is a Strategy and Innovation Management expert with more than 30 years of experience in healthcare, first as a clinical psychiatrist and then as a medical and commercial leader at Eli Lilly, Merck, Novartis, Sanofi, and Terumo BCT. She oversaw the launches of several first-in-class medications, which profoundly changed the standards of care and a vaccine with peak sales of US$3 billion dollars.
Kasia believes that innovation in healthcare matters only if patients have equitable access to it, as the treatment doesn’t work if barriers prevent its prescription, administration, or acceptance.
Anita is a dynamic, passionate and infectiously enthusiastic consultant focused on improving patient outcomes through pharmaceutical innovation, helping companies:
understand market dynamics and payer behavior in immunology, transplant and rare diseases
- develop predictive models to inform HTA submissions
- understand the implications of digital health and possibilities to use behavioral economics
- establish credibility for global Market Access insights through thought leadership, strategic vision and producing three product lines within 9 months
- understand the implications of the global evolution of the biosimilar market
Anita holds a Master of Arts degree in Economics from Dalhousie University, Nova Scotia, Canada, a Master of Business Administration degree from Kingston University, Surrey, UK, and Bachelor of Arts degree (Hons) in Economics from the University of Stirling, Scotland.
Michael Rosenblatt, M.D.
Michael’s career has been in academia, the pharma and biotech industries, and ventures. He is a physician-scientist, now advising life sciences funds, biotech and pharma companies, as well as serving on boards of directors and scientific advisory boards.
Most recently, Michael was the Chief Medical Officer of Flagship Pioneering, a Cambridge, MA-based firm that creates ...
... innovative biotech companies, including Moderna, where Michael served on the vaccine team and was a consultant to the chief medical officer. Previously, Michael was the Chief Medical Officer at Merck & Co. Inc.
Michael also served as Dean of Tufts University School of Medicine, and before that, Robert Ebert Professor of Molecular Medicine, and George R. Minot Professor at Harvard Medical School. He was President of Beth Israel Deaconess Medical Center and Director of the Harvard-MIT Division of Health Sciences and Technology.
Michael completed his internship, residency, and endocrinology training at the Massachusetts General Hospital. He received his MD magna cum laude from Harvard University, Cambridge and graduated summa cum laude from Columbia University, New York.
Arne Näveke, PhD
Arne is a Communications, Advocacy and Policy executive with more than 20 years of experience in the global biotech and biopharma industries, and in non-profit. He held leading roles at Freeline Therapeutics, Inc., Alexion Pharmaceuticals, Inc. (today AstraZeneca), the International AIDS Vaccine Initiative, GSK Vaccines, Sanofi Pasteur MSD, and Aventis (today Sanofi).
Arne is a trusted C-suite and expert counsel with sharp business and financial acumen, and strong scientific background.
A strategic thinker and storyteller, he is at home in all types of communications across the entire value chain, and a wide range of therapeutic areas and modalities, in common and rare diseases. Prior to his industry career, Arne was a journalist in top-tier broadcast and print media.
Arne has spent half of his career in Europe (Germany, France and Belgium) and the other half in the U.S. He is fluent in English, French and German. He holds a PhD in Biochemistry from the Ludwig-Maximilians University in Munich, Germany, and the Centre d’Etudes de Saclay, France, and a master’s degree in chemistry from the University of Hamburg, Germany.
Jared is a Managing Director at the Mizuho Group and is the firm’s Healthcare Equity Strategist. He provides healthcare sector/single stock views and related commentary to institutional investors across all components of the industry, including therapeutics, medical devices and diagnostics and services.
Jared has been named the top sector specialist by the annual Institutional Investor survey six times and is has been cited frequently by well-known financial media sources including The Wall St. Journal, Bloomberg and CNBC. Prior to Mizuho, he spent time in a similar role at Jefferies and held positions at UBS O’Connor and Bear Stearns as well.
Jared obtained his license as Certified Public Accountant (CPA) while at PricewaterhouseCoopers (PwC) and has an accounting background.
Stefan Dr. Walzer, PhD
Stefan specializes in pricing, health economics, payer strategies, dossier development and submission, and negotiations since 2004. He is the founder and CEO of MArS Market Access & Pricing Strategy GmbH in Germany, and P&N – Pricing & Negotiations in Health Care, Ltd. in Canada. Stefan also co-founded mAxInsights and Kukosha AI Ltd. that use AI to support customers in their Market Access activities.
Stefan invented the virtual reality negotiation platform used by The Negotiation Lab. He hosts the bi-weekly Market Access Podcast MAP, is co-editor of the book ‘Digital Health in Germany - Market Access for Innovation’ and the lead author of the book chapter ‘Reimbursement Value and Pricing in Business Planning in Health Care’, and he teaches Market Access at several universities in Germany.
Stefan started his career as a payer consultant for the successful global product launches by various global pharmaceutical and medical device/diagnostic companies. He co-authored more than 50 peer- reviewed scientific articles and more than 400 scientific abstracts. Stefan holds a PhD in Health Economics, a Master of Science in Economics, and a Diploma in Clinical Trials.
District Hall Boston
75 Northern Ave – Boston, MA 02210
Seminar – Registration
A Strategic Approach to the Successful Development of New Therapies End-to-End
Stefan Dr. Walzer, PhD
Founder and CEO, MArS Market Access & Pricing Strategy GmbH – Weil am Rhein, Germany Founder and CEO, P & N – Pricing & Negotiations in Healthcare, Ltd – Toronto, Canada Co-Founder, mAxInsights, de Haarlem, The Netherlands
Arne Näveke, PhD
Owner, AN Communications, LLC, Cohasset, MA Senior Strategic Advisor, Consilium Strategic Communications, London, UK/Boston, USA Communications Executive in the global biotech and biopharma industries, and in non-profit